Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities ...

GSK (GSK), a large British drug maker, is rallying 8% after reporting higher-than-expected fourth-quarter earnings per share and raising its long-term revenue guidance. GSK's Beat-and-Raise ...

Bernstein analyst Florent Cespedes maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £22.90. The company’s shares opened today at p1,443. ...

GSK's Q4 EPS and sales beat estimates Shares jump 6% R&D investment to focus on speciality medicines Feb 5 (Reuters) - GSK (GSK.L), opens new tab launched a 2 billion pounds ($2.5 billion) share ...

CEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over £31 billion, with specialty medicines driving performance. Core operating profit grew 13%, supporting a ...

Vivian Wan / Bloomberg via Getty Images GSK Plc's U.S.-listed shares surged Wednesday after the pharmaceutical firm boosted its long-term outlook and launched a $2.5 billion stock buyback on the ...

GSK shares added ~6% in London trading on Wednesday after the British drugmaker lifted its 2031 outlook and announced a new share buyback program alongside better-than-expected earnings for Q4 ...

(Bloomberg) -- GSK Plc plans to buy back £2 billion ($2.5 billion) of shares as it raised its long-term growth outlook on optimism around the drug pipeline. The British drugmaker boosted its 2031 ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. UK drugmaker GSK is struggling to convince the market that it can deliver on its plans to refill its ...

GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential functional cure for the infectious disease. On a media call Wednesday morning ...

GSK reported Q4 sales of $10.40B, surpassing estimates of $9.58B, while core EPS of $0.59 beat the consensus of $0.43 despite a 10% decline. Vaccine sales fell 14% to £2.21B, with Arexvy sales ...